Literature DB >> 10173073

Cost-effective management of diabetic foot ulcers. A review.

G Ragnarson-Tennvall1, J Apelqvist.   

Abstract

Foot lesions are common and serious complications in patients with diabetes mellitus. In recent years, several authors have, in addition to the medical aspects, focused on the high costs for treatment of this complication. However, few studies have performed a complete health-economic comparison and analysis of different treatments. This is probably related to the complexity of the problem and ethical difficulties in performing randomised clinical trials on these patients. Despite the lack of comparative health-economic studies, most authors conclude that amputations should be avoided if there is any possibility of saving the limb. This is not only because of the economic consequences-high costs for repeated hospitalisations, rehabilitation, home care and social-service support-associated with amputations, but also the quality-of-life aspects. Alternative treatment options might seem costly in the short term, but most cost-effectiveness analyses that also consider the long term perspective have concluded that treatment alternatives in which the limb is saved are more cost effective. Methodological aspects, such as the perspective of a study, may cause difficulties in comparing results between countries and settings. By using the societal perspective in economic studies, incentives to push costs from one sector to another might be avoided.

Entities:  

Mesh:

Year:  1997        PMID: 10173073     DOI: 10.2165/00019053-199712010-00005

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  74 in total

1.  [Cost-benefit analysis of saving the leg].

Authors:  H Bruijnen; H Loeprecht
Journal:  Langenbecks Arch Chir Suppl II Verh Dtsch Ges Chir       Date:  1989

2.  Lower-extremity amputation in people with diabetes. Epidemiology and prevention.

Authors:  D E Bild; J V Selby; P Sinnock; W S Browner; P Braveman; J A Showstack
Journal:  Diabetes Care       Date:  1989-01       Impact factor: 19.112

3.  Improved quality of diabetic foot care, 1984 vs 1990. Reduced length of stay and costs, insufficient reimbursement.

Authors:  G W Gibbons; E J Marcaccio; A M Burgess; F B Pomposelli; D V Freeman; D R Campbell; A Miller; F W LoGerfo
Journal:  Arch Surg       Date:  1993-05

4.  Prognostic value of systolic ankle and toe blood pressure levels in outcome of diabetic foot ulcer.

Authors:  J Apelqvist; J Castenfors; J Larsson; A Stenström; C D Agardh
Journal:  Diabetes Care       Date:  1989-06       Impact factor: 19.112

5.  The course of severe foot infection in patients with diabetes.

Authors:  E Criado; A A De Stefano; B A Keagy; G R Upchurch; G Johnson
Journal:  Surg Gynecol Obstet       Date:  1992-08

6.  Local signs and symptoms in relation to final amputation level in diabetic patients. A prospective study of 187 patients with foot ulcers.

Authors:  J Larsson; C D Agardh; J Apelqvist; A Stenström
Journal:  Acta Orthop Scand       Date:  1994-08

7.  Diabetes and its long-term complications in general practice: a survey in a well-defined population.

Authors:  K Reenders; E de Nobel; H J van den Hoogen; G E Rutten; C van Weel
Journal:  Fam Pract       Date:  1993-06       Impact factor: 2.267

8.  Re-intervention after vascular surgery for critical leg ischaemia.

Authors:  N J Cheshire; M A Noone; J H Wolfe
Journal:  Eur J Vasc Surg       Date:  1992-09

9.  Diabetes in the elderly: the Oxford Community Diabetes Study.

Authors:  H A Neil; A V Thompson; M Thorogood; G H Fowler; J I Mann
Journal:  Diabet Med       Date:  1989 Sep-Oct       Impact factor: 4.359

10.  Surgery for limb threatening ischaemia: a reappraisal of the costs and benefits.

Authors:  B F Johnson; L Evans; R Drury; D Datta; W Morris-Jones; J D Beard
Journal:  Eur J Vasc Endovasc Surg       Date:  1995-02       Impact factor: 7.069

View more
  6 in total

1.  Randomized prospective controlled trial of recombinant granulocyte colony-stimulating factor as adjunctive therapy for limb-threatening diabetic foot infection.

Authors:  F de Lalla; G Pellizzer; M Strazzabosco; Z Martini; G Du Jardin; L Lora; P Fabris; P Benedetti; G Erle
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

2.  The health status of diabetic patients receiving orthotic therapy.

Authors:  S Davies; O Gibby; C Phillips; P Price; W Tyrrell
Journal:  Qual Life Res       Date:  2000-03       Impact factor: 4.147

3.  Costs of deep foot infections in patients with diabetes mellitus.

Authors:  G R Tennvall; J Apelqvist; M Eneroth
Journal:  Pharmacoeconomics       Date:  2000-09       Impact factor: 4.981

Review 4.  Systematic review of economic evaluations of human cell-derived wound care products for the treatment of venous leg and diabetic foot ulcers.

Authors:  Astrid Langer; Wolf Rogowski
Journal:  BMC Health Serv Res       Date:  2009-07-10       Impact factor: 2.655

Review 5.  Cost of diabetic eye, renal and foot complications: a methodological review.

Authors:  Solène Schirr-Bonnans; Nadège Costa; Hélène Derumeaux-Burel; Jérémy Bos; Benoît Lepage; Valérie Garnault; Jacques Martini; Hélène Hanaire; Marie-Christine Turnin; Laurent Molinier
Journal:  Eur J Health Econ       Date:  2016-03-14

Review 6.  The economics of screening and treatment in type 2 diabetes mellitus.

Authors:  Maria Raikou; Alistair McGuire
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.